Navigation Links
Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session
Date:11/17/2010

ent over the current best standard of care available in the USA. We are now well positioned to advance RVX-208 to the next clinical trial having witnessed the substantial and consistent elevation of HDL by ApoA-I production; which strongly indicates that RVX-208 should remove unwanted plaque from the arterial wall which is our main goal."

Resverlogix Senior Vice President of Medical Affairs Dr. Jan Johansson stated, "In patients who received the newer class of statins and had baseline HDL below 45mg/dL, an important high-risk subpopulation, the middle dose of 200 mg saw the most pronounced increases of 12% in ApoA-I (p<0.002), 21% in HDL cholesterol (p<0.015) and 32% in large particle HDL (p<0.018). We are delighted by these results and now have a much better understanding of what doses to use and what patient population to target moving forward in our ASSURE Phase 2b trial." 

An additional presentation at the AHA meeting was given by Dr. Norman Wong, Chief Scientific Officer of Resverlogix, containing new data detailing the effects of RVX-208 in vivo. The presentation was titled "RVX-208: An Orally Administrated Small Molecule Reduces Atherosclerosis in ApoE Null Mouse and Raises ApoA-I/HDL in Humans". In the ApoE null mice model of atherosclerosis, the oral administration of RVX-208 reduced aortic plaques in two separate models.  The presented model showed plaque reductions of up to 41%. Resverlogix to Host Webcast on ASSERT Phase 2 Trial Results - change in time
Resverlogix Corp. will host a live teleconference and webcast today at 2:15 pm Central/1:15 pm Mountain time. The purpose of the teleconference is to discuss the top line results of the Company's Phase 2 clinical trial (ASSERT) for RVX-208. The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast will be posted onto the homepage of Resverlogix's website and can be accessed from the following addre
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data
2. Resverlogix Appoints Kenneth J. Zuerblis to Board of Directors
3. Resverlogixs Phase 2 ASSURE Trial Amended
4. Resverlogix Scientific Data Presented at EAS Congress
5. Resverlogix Completes Dosing for ASSERT Trial
6. Resverlogix Notice of Conference Call & Webcast for Year End Update
7. Resverlogix Activates First Site for ASSURE 1 Clinical Trial
8. Resverlogix Completes Patient Recruitment for ASSERT Trial
9. Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
10. Resverlogix Presenting at Biotech Showcase
11. Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014  Having the right people ... vital to accelerating business growth and achieving clinical and ... Association (AHA) Leadership Summit, July 20-22, 2014, in ... of hospital executives and healthcare experts discussing how partnerships ... Carrocino , President & Chief Executive Officer of Cape ...
(Date:7/23/2014)... Israel , July 23, 2014 ... a portfolio company of Trendlines Agtech , ... of Israel,s leading agricultural ... , Valentis,s technology combines nanocrystalline cellulose ... pulp waste, with additional nanoparticles to produce highly ...
(Date:7/23/2014)... regulated information -- UCB today announced an important advance ... topline results from the latest Phase 3 study ... evaluate the efficacy and safety of brivaracetam ... to placebo, as adjunctive treatment in adult focal ... despite treatment with one or two concomitant antiepileptic ...
(Date:7/23/2014)...  Sofinnova Ventures, a Menlo Park ... Sofinnova Venture Partners IX, L.P. at the hard cap ... fund target of $425 million. Sofinnova focuses ... with recent funds, SVP IX will provide capital primarily ... with select investments in earlier stage opportunities. Investments will ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2
... LARGO, Fla., Jan. 31 GeoPharma, Inc. (Nasdaq:,GORX) ... call to discuss the,results of its third fiscal ... 2008 at 11:30 a.m. (ET) with CEO, Mihir ... the conference call,by utilizing the following URL, http://www.theconferencingservice.com/prereg/key.process?key=PVYY97BW8 ...
... test can help doctors and clinicians identify best ... patients at risk of heart disease, BIRMINGHAM, Ala., ... drug combination point to the need for more,detailed cholesterol ... according to Atherotech, a cardio-diagnostic company that,has developed an ...
... Record Highs, BEDFORD, Mass., Jan. 31 Hologic, ... specializing in,diagnostics, imaging systems and interventional devices dedicated to,serving ... for the,quarter ended December 29, 2007., Highlights ... $371.4 million. -- Merger with Cytyc Corporation on ...
Cached Biology Technology:GeoPharma Announces Third Quarter Conference Call 2Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 2Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 3Hologic Announces First Quarter Fiscal 2008 Operating Results 2Hologic Announces First Quarter Fiscal 2008 Operating Results 3Hologic Announces First Quarter Fiscal 2008 Operating Results 4Hologic Announces First Quarter Fiscal 2008 Operating Results 5Hologic Announces First Quarter Fiscal 2008 Operating Results 6Hologic Announces First Quarter Fiscal 2008 Operating Results 7Hologic Announces First Quarter Fiscal 2008 Operating Results 8Hologic Announces First Quarter Fiscal 2008 Operating Results 9Hologic Announces First Quarter Fiscal 2008 Operating Results 10Hologic Announces First Quarter Fiscal 2008 Operating Results 11Hologic Announces First Quarter Fiscal 2008 Operating Results 12Hologic Announces First Quarter Fiscal 2008 Operating Results 13Hologic Announces First Quarter Fiscal 2008 Operating Results 14Hologic Announces First Quarter Fiscal 2008 Operating Results 15
(Date:7/23/2014)... Networking in personalized cancer medicine, (the WIN consortium), recently ... Thomas Jefferson University will be one of its ... prestigious group in the Tri-State Area. The goal of ... medicine to the patient by forging collaborations between partners ... in the WIN consortium means Jefferson cancer patients will ...
(Date:7/23/2014)... A sulfur-oxidizing bacterial group called SUP05 will play an ... the world,s oceans as oxygen minimum zones expand, according ... of the National Academy of Sciences . , University ... seasonally anoxic fjord, Canada,s Saanich Inlet, to chart how ... , "Our study paints a very detailed picture of ...
(Date:7/23/2014)... getting tangled and forming knots. Scientists study these knots ... them (e.g. useful for gene sequencing techniques). Cristian Micheletti, ... in Trieste and his team have been carrying out ... dynamics. In their latest paper, just published in the ... Di Stefano, first author and PhD student at SISSA, ...
Breaking Biology News(10 mins):New partnership brings more personalized cancer treatment to Philadelphia 2Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... Results of a new study show that episodes of reduced ... drought, greatly accelerated a rise in numbers of mountain pine ... The research is the first to chart the evolution of ... It compared patterns of beetle outbreaks in the two ...
... tools in the wild has been observed spontaneously making and using ... called ,Figaro, that has been reared in captivity and lives near ... wooden beams in its aviary, or twigs out of a branch, ... from the Universities of Oxford and Vienna filmed Figaro making and ...
... CORVALLIS, Ore. A national study of older Americans shows ... scientifically categorized as "frail" are five times more likely ... defined as "food insufficiency," than older adults who were not ... adults older than age 60 in the United States uses ...
Cached Biology News:Drought in 2001-2002 fueled Rocky Mountain pine beetle outbreak 2Drought in 2001-2002 fueled Rocky Mountain pine beetle outbreak 3Drought in 2001-2002 fueled Rocky Mountain pine beetle outbreak 4Cockatoo 'can make its own tools' 2Older adults who are frail much more likely to be food insufficient, according to national study 2
... Stabilizer is a bovine protein-free alternative to ... aqueous solution that contains non-toxic chemicals in ... 6.6 - 7.2, and does not contain ... activity of antibodies and other biomolecules that ...
... is designed to stabilize the biomolecules ... storage. There are neither animal ... is a convenient 10 times solution ... superior to other traditional lyophilizing additives ...
... The CERTOMAT IS, a true benchtop incubator-shaker, ... shakers. Having a footprint of 540 x ... a large incubation chamber (370 x 505 x ... orbits, the CERTOMAT IS is ideal for shaking ...
... of the smallest thermal cyclers on the market, ... the 0.5ml (20 samples) or 0.2ml microtube (25 ... heating and cooling rate of 3.6C/sec and 2.0C/sec ... Fast track programming with new quick dial ...
Biology Products: